Verastem, Inc. (VSTM)
-NasdaqGM 9.26 
0.08(0.82%) 12:10PM EDT - Nasdaq Real Time Price
| Prev Close: | 9.18 |
|---|
| Open: | 9.15 |
|---|
| Bid: | 9.22 x 100 |
|---|
| Ask: | 9.29 x 400 |
|---|
| 1y Target Est: | 17.17 |
|---|
| Beta: | 1.251 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 9.05 - 9.31 |
|---|
| 52wk Range: | 6.25 - 12.00 |
|---|
| Volume: | 8,151 |
|---|
| Avg Vol (3m): | 20,136 |
|---|
| Market Cap: | 197.03M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.69 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Verastem to Present at the 2013 ASCO Annual MeetingBusiness Wire(Thu 7:54AM EDT)
- Verastem to Present at Upcoming ConferencesBusiness Wire(Tue, May 21)
- VERASTEM, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Friday 5/17 Insider Buying Report: WFR, VSTMat Forbes(Fri, May 17)
- Verastem Hires a CFOat Motley Fool(Wed, May 15)
- CFO Moves: Cigna, Edwards Lifesciences, Verastemat The Wall Street Journal(Tue, May 14)
- Verastem appoints Jack Green as CFOtheflyonthewall.com(Tue, May 14)
- Jack Green Joins Verastem as Chief Financial OfficerBusiness Wire(Tue, May 14)
- VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecuEDGAR Online(Tue, May 14)
- Top Life Science Investors Of 2013at Forbes(Thu, May 9)
- Verastem Reports First Quarter 2013 Financial and Corporate ResultsBusiness Wire(Thu, May 9)
- VERASTEM, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Verastem to Present at Upcoming ConferencesBusiness Wire(Wed, May 8)
- Monday 4/22 Insider Buying Report: WAG, VSTMat Forbes(Mon, Apr 22)
- Verastem to Present at Upcoming ConferencesBusiness Wire(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics.
View More